Safety and Efficacy Study of TNX-102 SL in Patients With Military-related PTSD (HONOR)

Tonix Pharmaceuticals

Status and phase: Terminated; Phase 3

Conditions: PTSD

Treatments: Drug: TNX-102 SL; Drug: Placebo SL Tablet

Study type: Interventional

Funder types: Industry

Identifiers

NCT03062540

TNX-CY-P301

Details and patient eligibility

About

This is a 12-week, multicenter, randomized, double-blind, placebo-controlled, fixed-dose study that will investigate the efficacy and safety of 5.6 mg TNX-102 SL (2 x 2.8 mg tablets)-a sublingual formulation of cyclobenzaprine. Following successful screening and randomization, eligible patients will have a telephonic visit at week 2 and then return regularly to the study clinic for monthly visits for assessments of efficacy and safety.

Enrollment: 358 patients

Sex: All

Ages: 18 to 75 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Male or female between 18 and 75 years of age, who have served in any branch of the military.
• Diagnosed with current PTSD as determined by the Clinician-Administered PTSD Scale (CAPS-5) for DSM-5.
• Index trauma(s) resulting in PTSD must meet DSM-5 criterion A for PTSD as described in CAPS-5, have occurred in 2001 or later, be military service related.
• Willing to refrain from use of all other formulations of cyclobenzaprine.
• Willing and able to refrain from antidepressants and other excluded medications.
• Capable of reading and understanding English and able to provide written informed consent.
• If female, either not of childbearing potential or practicing a medically acceptable method of birth control throughout the study.
• Willing and able to comply with all protocol-specified requirements.

Exclusion criteria

• Increased risk of suicide, based on the investigator's judgment that is of a severity that is not appropriate for outpatient management, or that warrants additional therapy excluded by the protocol.
• Significant (e.g., moderate or severe) comorbid traumatic brain injury (TBI) by history.
• Severe depressive symptoms at screening or baseline.
• Clinically significant laboratory abnormalities based on screening laboratory tests and/or medical history in the investigator's opinion.
• Use of antidepressant medication within 2 months of baseline.
• Female patients who are pregnant or lactating.
• History of serotonin syndrome, severe allergic reaction or bronchospasm or known hypersensitivity to cyclobenzaprine or the excipients.
• Seizure disorder.
• Patients with a body mass index (BMI) > 45.
• Has received any other investigational drug within 30 days before Screening.
• Previous participation in any other study with TNX-102 SL.
• Family member of investigative staff.

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Quadruple Blind

---

358 participants in 2 patient groups, including a placebo group

TNX-102 SL Tablet, 5.6 mg

Experimental group

Description:

2 x TNX-102 SL, 2.8 mg Tablets taken sublingually each day at bedtime for 12 weeks.

Treatment:

Drug: TNX-102 SL

Placebo SL Tablet

Placebo Comparator group

Description:

2 x Placebo Tablet taken sublingually each day at bedtime for 12 weeks.

Treatment:

Drug: Placebo SL Tablet